|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 149.23 USD | -4.15% |
|
-5.24% | +87.36% |
| 03/06 | 'It's still working': More are living with cancer as era of targeted drugs takes hold | RE |
| 02/06 | Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says | MT |
| Capitalization | 3.17TCr 2.75TCr 2.52TCr 2.37TCr 4.42TCr 3,02300Cr 4.49TCr 30TCr 12TCr 1,46200Cr 12TCr 12TCr 5,08400Cr | P/E ratio 2026 * |
-18.7x | P/E ratio 2027 * | -26.7x |
|---|---|---|---|---|---|
| Enterprise value | 2.84TCr 2.46TCr 2.26TCr 2.12TCr 3.95TCr 2,70700Cr 4.02TCr 27TCr 10TCr 1,30900Cr 11TCr 10TCr 4,55200Cr | EV / Sales 2026 * |
284x | EV / Sales 2027 * | 34.1x |
| Free-Float |
97.98% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Revolution Medicines, Inc.
| 1 day | -4.15% | ||
| 1 week | -5.24% | ||
| Current month | -5.24% | ||
| 1 month | -1.22% | ||
| 3 months | +51.66% | ||
| 6 months | +87.38% | ||
| Current year | +87.36% |
| 1 week | 148.15 |  | 166.5 |
| 1 month | 140.53 | | 166.5 |
| Current year | 76.28 | | 166.5 |
| 1 year | 34 | | 166.5 |
| 3 years | 15.44 | | 166.5 |
| 5 years | 14.08 | | 166.5 |
| 10 years | 14.08 | | 166.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Goldsmith
CEO | Chief Executive Officer | 64 | 01/11/2014 |
Jack Anders
DFI | Director of Finance/CFO | 49 | 01/10/2018 |
| Chief Tech/Sci/R&D Officer | - | 01/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Goldsmith
CHM | Chairman | 64 | 01/01/2020 |
| Director/Board Member | 68 | 01/03/2015 | |
Alexis Borisy
BRD | Director/Board Member | 54 | 01/11/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 26/05 | Fiscal year | See Remarks | 9,363 | 0.0044% | ||
| 27/04 | Fiscal year | See Remarks | 9,360 | 0.0047% | ||
| 15/04 | Fiscal year | Chief Executive Officer | 3,60,000 | 0.1817% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.15% | -5.24% | +263.18% | +452.70% | 3.17TCr | |
| -1.18% | -2.96% | -15.31% | -18.77% | 4.27TCr | |
| -1.84% | +0.68% | +20.44% | -10.72% | 3.06TCr | |
| -3.51% | -6.19% | +5.57% | +19.44% | 3TCr | |
| -2.89% | -6.70% | +14.76% | +14.13% | 2.42TCr | |
| -0.18% | +3.94% | +11.24% | +4.51% | 1.32TCr | |
| -3.83% | -6.10% | - | - | 1.31TCr | |
| -0.97% | +1.60% | +53.20% | +106.80% | 1.3TCr | |
| -0.87% | -2.64% | +111.05% | +71.89% | 1.23TCr | |
| -2.19% | +9.83% | +7.43% | -33.25% | 1.14TCr | |
| Average | -2.16% | -1.38% | +52.39% | +67.41% | 2.22TCr | |
| Weighted average by Cap. | -2.32% | -2.46% | +53.24% | +77.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10Cr 8.66Cr 7.94Cr 7.47Cr 14Cr 952.56Cr 14Cr 94Cr 37Cr 460.67Cr 38Cr 37Cr 1.6TCr | 85Cr 73Cr 67Cr 63Cr 117.72Cr 8.06TCr 119.56Cr 798.5Cr 310.77Cr 3.9TCr 317.44Cr 310.53Cr 14TCr |
| Net income | -164.57Cr -142.52Cr -130.77Cr -123.04Cr -229.16Cr -16TCr -232.74Cr -1.55TCr -604.95Cr -7.58TCr -617.94Cr -604.5Cr -26TCr | -111.02Cr -96Cr -88Cr -83Cr -154.59Cr -11TCr -157.01Cr -1.05TCr -408.1Cr -5.12TCr -416.86Cr -407.79Cr -18TCr |
| Net Debt | -332.32Cr -287.79Cr -264.07Cr -248.44Cr -462.73Cr -32TCr -469.97Cr -3.14TCr -1.22TCr -15TCr -1.25TCr -1.22TCr -53TCr | -287.88Cr -249.3Cr -228.75Cr -215.22Cr -400.85Cr -27TCr -407.12Cr -2.72TCr -1.06TCr -13TCr -1.08TCr -1.06TCr -46TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | 149.23 $ | -4.15% | 21,40,414 |
| 04/26/04 | 155.69 $ | -0.19% | 26,09,527 |
| 03/26/03 | 155.99 $ | +3.09% | 20,08,033 |
| 02/26/02 | 151.31 $ | -7.56% | 37,50,390 |
| 01/26/01 | 163.68 $ | +3.94% | 67,30,919 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RVMD Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition